# Marijuana Opponents Preview Arguments For Next Week’s Rescheduling Hearing In New Filings > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/marijuana-opponents-preview-arguments-for-next-weeks-rescheduling-hearing-in-new-filings/ > **Published:** 2026-06-27T07:18:48-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:21:09-04:00 > **Clinical Summary:** Understand what cannabis brain reward pathways research actually proves about disorder risk—and what it doesn't. Clinical evidence explained. --- ✦ New CED Clinical Relevance #57 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyTHCSafetyMental HealthNeurologyResearchPain Why This Matters If cannabis is rescheduled to a lower DEA classification, clinicians will need updated evidence-based screening and treatment protocols for [Cannabis Use Disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/), particularly given documented neurobiological changes in brain reward systems from THC exposure. Understanding the neurobiology of [cannabis dependence](https://cedclinic.com/ptsd-cannabis-dependence-veterans-social-support/) becomes clinically essential as legal access expands and more patients present with substance use concerns that current clinical practice may underrecognize or undertreate. Regulatory changes based on rescheduling hearings will likely affect prescription options, insurance coverage, and clinical guidelines that shape how providers counsel patients about cannabis risks and manage related disorders. Clinical Summary Federal opponents of cannabis rescheduling have filed arguments emphasizing the [neurobiological mechanisms](https://cedclinic.com/cannabis-tolerance-behavioral-models/) by which repeated THC exposure alters brain reward pathways, potentially leading to [Cannabis Use Disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) and substance dependence. These filings will be presented at an upcoming DEA hearing on whether cannabis should remain a Schedule I controlled substance, with opponents contending that the drug’s abuse potential justifies its current restrictive classification. While the clinical literature supports that cannabis use can precipitate problematic use patterns in susceptible populations, the framing of this evidence in scheduling debates may not fully account for cannabis’s documented therapeutic applications or the variable risk profiles across different patient populations and use patterns. Clinicians should recognize that scheduling status and clinical evidence regarding therapeutic benefit versus harm risk are distinct considerations, and that regulatory decisions may not always align with the nuanced pharmacology and clinical outcomes relevant to [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). The practical takeaway for clinicians is to maintain independent clinical judgment regarding cannabis’s risks and benefits for individual patients while remaining aware that DEA scheduling decisions are primarily driven by federal drug policy considerations rather than comprehensive clinical evidence review. Dr. Caplan’s Take “What we know from peer-reviewed human studies is that regular THC exposure can indeed modulate dopaminergic pathways, and a subset of users do develop [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) with clinically meaningful consequences, though the incidence and severity vary considerably across populations. The challenge in clinical practice is that individual susceptibility differs markedly, and we still need better predictive markers to identify who is at genuine risk before exposure occurs.” Clinical Perspective 🧠 While cannabis rescheduling discussions often focus on legal and regulatory arguments, the neurobiology of repeated THC exposure and its potential to alter reward circuitry merits serious clinical consideration. The concern that chronic use may precipitate cannabis use disorder through neuroadaptive changes is supported by emerging neuroscience, though the clinical significance varies considerably based on age of initiation, frequency of use, individual genetic vulnerability, and THC concentration in available products. Healthcare providers should recognize that this risk exists alongside the documented therapeutic utility of cannabinoids for certain conditions, and that regulatory status does not necessarily reflect clinical evidence for either harm or benefit. In practice, clinicians can acknowledge both the neuropharmacological mechanisms underlying dependence potential and the heterogeneity of individual risk profiles when counseling patients about cannabis use, particularly adolescents and young adults whose brain development may confer greater vulnerability to these effects. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Marijuana%20Opponents%20Preview%20Arguments%20For%20Next%20Week%27s%20Rescheduling%20Hearing%20In%20New%20Filings%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D67571)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D67571)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Marijuana%20Opponents%20Preview%20Arguments%20For%20Next%20Week%27s%20Rescheduling%20Hearing%20In%20New%20Filings%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D67571)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.marijuanamoment.net/marijuana-opponents-preview-arguments-for-next-weeks-rescheduling-hearing-in-new-filings/](https://www.marijuanamoment.net/marijuana-opponents-preview-arguments-for-next-weeks-rescheduling-hearing-in-new-filings/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).